Core Viewpoint - The insurance industry must adapt to the evolving landscape shaped by healthcare reforms, focusing on commercial health insurance as a complementary role to basic medical insurance, while enhancing service integration and social responsibility [5][6]. Group 1: Market Dynamics - The current healthcare reform is reshaping China's multi-tiered medical security system, with commercial health insurance expected to play a supplementary role to the basic medical insurance system, which covers 1.35 billion people, achieving a coverage rate of 95% [5]. - The recent reforms in medical payment and catalog have created opportunities for commercial insurance to fill gaps left by basic insurance, indicating a shift towards a multi-layered structure where commercial insurance becomes a co-builder of the system [5]. Group 2: Product Development - Life insurance companies possess a natural advantage in long-term and holistic solutions, but face challenges in designing products for high-risk groups, such as those with pre-existing conditions, due to the complexity of risk assessment and market acceptance [6]. - The industry needs to develop more inclusive risk identification models and underwriting standards, as well as promote data sharing and policy collaboration to ensure the sustainability of commercial health insurance [6]. Group 3: Service Innovation - There is a growing demand for health insurance services tailored for expatriates, particularly those from state-owned enterprises stationed overseas, which includes not only basic medical coverage but also emergency transport and family visit services [7]. - The establishment of effective service mechanisms for expatriates faces challenges such as complex risk assessments and high dependency on qualified rescue service providers, which can increase costs [7]. - The industry aims to enhance overall underwriting capacity and service levels through collaborative platforms that facilitate data sharing and capability integration [8].

Core Insights - In 2024, the company expects a decline in both revenue and net profit, with projected figures of 3.898 billion and 392 million respectively, representing year-on-year decreases of 19.86% and 15.58% [1] - The first quarter of 2024 continues to show pressure on performance, with revenue of 878 million, down 35.38% year-on-year, and net profit of 83.41 million, down 38.37% [1] - The decline in first-quarter revenue is primarily attributed to a decrease in sales of the core injection product, Heat Toxicity Ning Injection [1][2] Product Performance - The core injection products have historically driven high growth, with Heat Toxicity Ning Injection sales exceeding 1 billion in 2013, but experiencing significant fluctuations due to policy changes [2] - The 2023 National Medical Insurance Directory allowed for increased sales of Heat Toxicity Ning Injection, reaching 6.077 million units, but sales fell to 4.195 million units in 2024, with inventory levels increasing by 759.11% [2] - Ginkgo Biloba Diterpene Amine Injection has also contributed to revenue growth, but its price dropped significantly after negotiations, limiting its growth potential [3] - The company’s oral liquid product, Jin Zhen Oral Liquid, has shown inconsistent sales performance, with year-on-year changes of 74.81%, -22.67%, and 5.13% from 2022 to 2024 [3] Financial Overview - In the first quarter, the injection product category generated approximately 340 million in revenue, down 36.86% year-on-year [4] - The overall revenue for the company in the first quarter was 867.22 million, with a total revenue decline of 35.79% [7] - The company reported a significant decline in operating cash flow, down 59.9% to 77 million in the first quarter, raising concerns about balancing cash flow health with long-term investments [9] New Product Developments - The company has received approvals for several new traditional Chinese medicine products, but their contribution to overall revenue remains limited, with a 10.34% decline in revenue from granules and powders in 2024 [6] - The company has not disclosed sales figures for the "Scattering Cold and Dampness Granules," a product related to COVID-19 treatment, despite investor inquiries [8]

Group 1 - The core viewpoint is that the integration of medical, pharmaceutical, and insurance sectors is essential for establishing a high-quality multi-tiered healthcare system, with commercial health insurance playing a crucial role in this transformation [1][5][8] - Medical insurance has surpassed critical illness insurance to become the leading segment in the health insurance market, with a projected premium growth rate exceeding 10% in 2024, compared to the overall health insurance growth rate of 8.2% [2][3] - The current healthcare insurance landscape is evolving, with medical insurance premiums expected to account for approximately 44% of total health insurance premiums in 2024, marking a significant shift in the market structure [2][3] Group 2 - The integration of medical, pharmaceutical, and insurance sectors is still in its early stages, facing challenges such as insufficient collaboration, data barriers, and a shortage of specialized talent [1][5][6] - The commercial health insurance sector has shown rapid growth, particularly in urban customized medical insurance, but it still struggles to meet the needs of specific groups, such as those with chronic diseases [6][7] - The need for policy support, improved data connectivity, and the establishment of a robust infrastructure is critical for advancing the integration of medical, pharmaceutical, and insurance sectors [7][8][9] Group 3 - The innovative pharmaceutical market in China is projected to reach 162 billion yuan in 2024, with personal cash expenditures accounting for 49% and commercial health insurance payouts only about 7.7% [3] - The shift from a passive payment model to an active management approach in commercial health insurance is necessary for enhancing the value and efficiency of healthcare delivery [9] - The development of a shared infrastructure, including a unified directory system and standardized treatment consensus, is essential for fostering collaboration among stakeholders in the healthcare ecosystem [8][9]

Core Insights - The development of commercial health insurance is entering a critical phase, focusing on three key tasks: comprehensive coverage, upgraded services, and innovative inclusivity to provide better healthcare services to a wider population [1][2] - The ongoing healthcare reform has clarified the basic coverage role of medical insurance, leading to an explosion in demand for high-end medical services as patients increasingly seek innovative treatments and quality healthcare options [1][2] Industry Trends - There is a growing trend among patients to choose private, specialized, and international medical services, reflecting a strong desire for quality and freedom in healthcare [1][2] - The health insurance sector is tasked with complementing basic medical insurance while linking to high-quality medical resources and expanding coverage boundaries [1][2] Company Innovations - Megxin Health is innovating by constructing quality medical plans that expand coverage for innovative drugs, upgrade outpatient responsibilities, and extend hospitalization coverage to international and private hospitals [2] - The company is also enhancing user experience through advanced technology, addressing common challenges in claims processing such as cumbersome material submission and complex insurance terms [2][3] Market Potential - According to a report by Boston Consulting Group and Zhongyin Securities, the potential market share for generative AI in the health insurance sector is projected to grow at a compound annual growth rate of 85%, indicating significant commercial potential [3] - Megxin Health has developed the ClaimMaster intelligent claims processing system, which aims to redefine the standards of commercial health insurance claims services [3]

Core Viewpoint - The implementation of instant settlement for medical insurance funds in Hebei Province is a significant reform aimed at improving the efficiency of healthcare financing and ensuring timely payments to medical institutions [1] Group 1: Medical Insurance Fund - The medical insurance fund is described as "life-saving money" for the public, serving as a crucial source of funding for medical services and pharmaceutical products [1] - As of May 8, a total of 20.17 billion yuan has been allocated to 18,413 designated medical institutions [1] Group 2: Instant Settlement Reform - The instant settlement reform is highlighted as an important initiative in this year's medical insurance reform efforts [1] - The reform allows for daily reimbursement of medical expenses to designated medical institutions, enhancing cash flow and operational efficiency [1]

Meeting Format and Details - The annual general meeting will be held on May 22, 2025, at 14:00 in Jinhua, Zhejiang Province [1] - Voting will be conducted both on-site and online, with specific time slots for each method [1] Attendance and Agenda - Shareholders registered by May 15, 2025, will be eligible to attend and vote [3] - The agenda includes listening to the independent director's report, appointing vote counters, discussing proposals, and legal opinions from witnessing lawyers [3] Business Performance Overview - In 2024, the company achieved a revenue of 2.876 billion yuan, a decrease of 0.58% year-on-year, facing challenges in both the construction materials and pharmaceutical sectors [4] - The construction materials segment is undergoing a transformation towards green and digital practices, with significant investments in energy-saving technologies [4] - The pharmaceutical segment has improved management and production efficiency, with several products receiving market approvals [5] Industry Trends and Company Strategy - The construction materials industry is expected to face continued demand decline due to real estate market stabilization and overcapacity issues [6][7] - The pharmaceutical industry is shifting towards innovation-driven growth, with a focus on enhancing research and development capabilities [7] - The company aims to extend its core businesses in construction materials and pharmaceuticals while maintaining a diversified business framework [8] Financial Performance - Total liabilities increased to 2.029 billion yuan, a rise of 28.54% from the previous year, with current liabilities accounting for a significant portion [16] - The net profit for 2024 was approximately 132.53 million yuan, reflecting a 49.72% increase year-on-year [16][25] - Cash flow from operating activities showed a substantial increase of 871.29%, reaching 412.11 million yuan [26] Profit Distribution - The company plans to distribute dividends amounting to 34.41 million yuan, adhering to its profit distribution policy [12]

Core Insights - The company achieved a total revenue of 1.004 billion yuan in 2024, marking a year-on-year growth of 5.12% [1][4] - Net profit attributable to shareholders was 220 million yuan, with a year-on-year increase of 7.43%, but the growth rate significantly slowed compared to 2023 [1][4] - The growth rate of non-recurring net profit dropped from 22.97% in 2023 to 2.89% in 2024, indicating a weakening in the company's profitability excluding non-recurring items [1][4] Revenue and Profit Performance - The company's total revenue surpassed 1 billion yuan for the first time, driven by the sustained promotion of core products and optimization of sales channels [4] - However, the slowdown in net profit growth raises concerns, with a decline from 22.31% in 2023 to 7.43% in 2024 [4] - Rolling quarter-on-quarter data shows total revenue grew by 4.05%, while net profit and non-recurring net profit experienced negative growth of -2.56% and -6.14%, respectively [4] Core Product Performance - Core products such as Si Mo Tang oral liquid and Suo Quan capsules performed well in the market, with Si Mo Tang being a unique product under the national medical insurance directory [4] - The company secured selection in multiple centralized procurement projects, reinforcing its market position [4] - Other products like Suo Quan capsules and Tian Ma Xing Nao capsules have also entered various county-level medical community directories, indicating successful market penetration [4] Market Challenges - The company faces significant market pressure due to deepening medical insurance reforms and the expansion of centralized procurement, which may lead to price reductions and profit margin compression [5] - Ongoing medical anti-corruption efforts impose higher compliance requirements on the company's marketing strategies, making it crucial to maintain competitiveness while adhering to regulations [5] R&D Investment Trends - R&D investment decreased to 39.32 million yuan in 2024, a decline of 7.28% year-on-year, with R&D expenditure accounting for 3.91% of total revenue, down 0.53 percentage points from 2023 [6] - The reduction in R&D spending could hinder the launch of new products and upgrades of existing ones, potentially weakening market competitiveness [6] - Despite some achievements in R&D, such as obtaining registration certificates for certain products, the overall decline in investment raises concerns about future growth [6] Overall Assessment - The company maintained revenue and net profit growth in 2024, but the slowdown in growth rates and decline in R&D investment highlight challenges in adapting to market competition and policy changes [6] - Future strategies should focus on enhancing core product competitiveness, increasing R&D investment, and optimizing cost structures for sustainable development [6]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《2024 年年度報告摘要》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 吳以芳 中國，上海 2025 年3 月2 5 日 於本公告日期，本公司之執行董事為吳以芳先生、王可心先生、關曉暉女士及文德鏞先生；本公司之非執 行董事為陳 啟 宇先生、徐曉亮先生、潘東輝先生及陳玉卿先生；以及本公司之獨立非執行董事為李玲女士、 湯谷良先生、王全弟先生及余梓山先生。 * 僅供識別 上海复星医药（集团）股份有限公 ...